Heart disease research

cardio vascular disease


blog-post

Almost all Australians have some form of plaque build up

30% of Australians die from heart attack


Coronary artery disease is the clogging or blockage of the coronary arteries caused by atherosclerosis.
High cholesterol diets, lack of exercise or your genetics can cause cholesterol to build up in the arteries. 52 Australians die each day from heart attack.
What if we could simply melt the plaque away?

This can be reversed


blog-post

Scientists discover new treatment

blog-post

Mice artery showing substantial reduction in plaque

German scientists discover treatment to remove plaque


In 2016 a team of scientists from Germany's Bonn University discovered a new compound that reduced plaque in mice by over 40% in as little as 4 weeks.

The new cyclodextrin compound (CAVADEX®) was also tested on human plaque and they discovered it affected the plaque in a similar way.

breakthrough discovery !!


Link to the published article



CAVADEX® entraps and removes harmful cholesterol from plaque

blog-post

cavadex® reduces plaque in humans

CAVADEX® developed by Cholrem Pty Ltd

blog-post

Angiogram: First patient has substantial plaque reduction in just 4 weeks

CAVADEX® melts away plaque


CAVADEX® was administered to our first patient in our Melbourne clinic in April 2019 and within 4 weeks the plaque was significantly reduced!

CAVADEX® circulates around the cardiovascular system removing built up cholesterol and plaque resulting in significant plaque reduction in as little as 4 weeks.

CAVADEX® is absorbed via intravenous application, as an enema and now as a low absorption tablet.

Regular low doses of CAVADEX® can have a significant effect on plaque build up


Click here to
learn more about CAVADEX®

1 year update

It has been just over a year since our first patient was administered CAVADEX®. The patient was administered a 4-week intravenous treatment and then administered RemChol twice a week for 52 weeks. The patient had 3 angiograms during that time.

blog-post

First patient angiograms over a one-year period

Cholrem research clinic

blog-post

our Melbourne clinic is now open


cholrem research


Our new clinic in Melbourne is at the leading edge of cyclodextrin research for the treatment of heart disease and the prevention and reduction of arterial plaque.

products containing CAVADEX®



RemChol Tubes

remchol for home

RemChol enemas contain 4000mg of CAVADEX® and can deliver up to 1000mg of CAVADEX® absorbed into the blood stream per dose. RemChol can be applied as often as once daily.


Regular low doses of CAVADEX® can have a significant effect on plaque build up.


blog-post

CAVADEX® Tablets

CAVADEX® tablets can deliver up to 120mg of CAVADEX® absorbed into the blood stream. Taken daily, CAVADEX® tablets can provide a regular low dose of CAVADEX® to your arteries.


Available soon


blog-post
blog-post
blog-post

cholrem news



Related Articles


"Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques..."

nature.com : Molecule melts away cholesterol.


"Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques..."

sciencedaily.com : Drug used for rare disease may be able to treat heart disease.


"Soaked up cholesterol and removed it..."

sciencedaily.com : New hope for treating atheriosclerosis


"have the potential in lowering deaths caused by atherosclerosis..."

ntnu.co : Can a sugar treat atherosclerosis?


"can actually solubilize cholesterol and dissolve the plaques..."

huffpost.com : Cholesterol sweet spot.




Research studies


"Alzheimer disease"
A study on the effects of HP-B-CD in transgenic mice with Alzheimer disease showed a dramatic reduction in symptoms and significantly improved spatial learning and memory deficits in mice. The study concluded HP-B-CD could be a novel therapeutic strategy for Alzheimer disease.



"Diabetic kidney disease"
HP-B-CD has shown promising pre-clinical results in kidney disease. Progression of kidney disease was prevented in mouse models and diabetic kidney disease was prevented or partially prevented in two pre-clinical studies.



"Non-alcoholic fatty liver disease"
Several studies have shown that HP-B-CD reduces liver cholesterol and cholesterol crystals. HP-B-CD has a substantial effect on cholesterol distribution and cholesterol transporters.



"Improved eyesight"
Lipofuscin accumulation in the retinal pigment epithelium is a hallmark of aging. A study was done on the effects of cyclodextrin and found that the beta-cyclodextrin can bind retinal lipofuscin, prevent its oxidation and remove it.
Cholrem patients have also reported improved vision after treatments of CAVADEX®.